Entrada Therapeutics, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $905,000 (-43.9% year over year) and diluted EPS of -$0.94. It usually reports 8–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 7, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 8, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
1
-43.9%
|
-40
+10.0%
|
-0.94
+11.3%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-53.9%
|
-43
+0.8%
|
-1.01
+2.9%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
-95.7%
|
-40
-128.9%
|
-0.95
-126.2%
|
|
Jan 8, 2026
8 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1
-96.5%
|
-39
-3562.8%
|
-0.94
-3697.0%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2
-91.8%
|
-44
-214.5%
|
-1.06
-202.9%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
2
-97.9%
|
-43
-178.3%
|
-1.04
-167.1%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
21
-65.2%
|
-17
-173.8%
|
-0.42
-161.8%
|
|
Jan 15, 2025
15 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
37
-10.6%
|
1
+111.9%
|
0.03
+108.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1689375
- Former names
- CycloPorters, Inc. (until Nov 10, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.